Missouri is currently home to 1891 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
NCT03509961
Recruiting
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regime... Read More
Gender:
ALL
Ages:
Between 1 year and 25 years
Trial Updated:
05/01/2025
Locations: Children's Mercy Hospital, Kansas City, Missouri
Conditions: B-cell Acute Lymphoblastic Leukemia
Register for Updates
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06911112
Recruiting
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Neurocrine Clinical Site, Saint Charles, Missouri
Conditions: Major Depressive Disorder
Register for Updates
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
NCT06555328
Recruiting
The study duration for an individual subject includes screening (14 days), the treatment period (28 days) and the observational follow-up period of 28 days, in total 70 days ± 6 days. All subjects will receive IMP for 28 days followed by one End of Study (EOS) visit, 4 weeks after EOT visit.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/30/2025
Locations: MediSearch LLC, Saint Joseph, Missouri
Conditions: Chronic Urticaria, Idiopathic, Hidradenitis, Hidradenitis Suppurativa
Register for Updates
AltaValve Pivotal Trial
NCT06465745
Recruiting
This is a prospective, single arm, multicenter, clinical trial designed to evaluate the safety and performance of the AltaValve System for the treatment of mitral regurgitation in a targeted patient population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Washington University, Saint Louis, Missouri
Conditions: Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation, Mitral Incompetence
Register for Updates
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461
Recruiting
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/30/2025
Locations: BVL Clinical Research, Liberty, Missouri
Conditions: Crohn's Disease
Register for Updates
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
NCT05538208
Recruiting
The study is a 1-year 2-part double-blinded placebo controlled 2-arm clinical trial. Treatment arms are (1) MMF dosed as per body-surface area (MMFBSA; 600mg/m2 body surface area per dose about every 12 hours) and (2) pharmacokinetically-guided precision-dosing of MMF (MMFPK; MMF dosed twice daily to achieve an area under the concentration-time curve (AUC0-12h) of MPA \>60-70 mg\*h/L. The study goal is to determine the safety and efficacy of MMFPK compared to MMFBSA for the treatment of prolifer... Read More
Gender:
ALL
Ages:
Between 8 years and 20 years
Trial Updated:
04/30/2025
Locations: Washington University in St. Louis School of Medicine, St. Louis, Missouri
Conditions: Lupus Nephritis
Register for Updates
An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
NCT05364086
Recruiting
This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment. Collecting samples of blood and saliva and health and treatment information from racially diverse patients receiving immune checkpoint inhibitor treatment over time may help doctors better understand health care disparities among all cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Parkland Health Center - Farmington, Farmington, Missouri
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Register for Updates
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
NCT04929028
Recruiting
This phase II trial studies the side effects of chemotherapy and intensity modulated radiation therapy in treating patients with low-risk HIV-associated anal cancer, and nivolumab after standard of care chemotherapy and radiation therapy in treating patients with high-risk HIV-associated anal cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: AIDS-Related Anal Carcinoma, Anal Squamous Cell Carcinoma, HIV Infection, Rectal Squamous Cell Carcinoma, Stage III Anal Cancer AJCC v8, Anal Margin Squamous Cell Carcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Anal Non-Keratinizing Squamous Cell Carcinoma, Stage IIB Anal Cancer AJCC v8
Register for Updates
Ultrasound and Photoacoustic Imaging for Enhanced Differential Diagnosis of Rectal Cancer
NCT04339374
Recruiting
The purpose of this study is to demonstrate the functionality of a novel endorectal photoacoustic ultrasound imaging modality in humans with rectal cancer. The study involves testing a previously developed endorectal device to determine its ability to accurately assess rectal tumor response to preoperative treatment. Investigators hypothesize that a co-registered photoacoustic ultrasound endorectal device can significantly reduce unnecessary surgeries in rectal cancer patients with complete clin... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
04/30/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Rectal Cancer, Colorectal Cancer
Register for Updates
Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
NCT03996265
Recruiting
This phase III trial studies how well bupropion works in reducing cancer related fatigue in cancer survivors. Cancer and its treatment can cause fatigue. Bupropion is a drug that is used to treat depression, as well as to help people quit smoking. It belongs to the family of drugs called antidepressants and works by increasing certain types of activity in the brain. Bupropion may reduce cancer-related fatigue by causing changes in inflammation and stress hormones.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri
Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Register for Updates
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
NCT03516708
Recruiting
The purpose of this research study is to evaluate epacadostat when given with routine radiation therapy and chemotherapy (capecitabine and oxaliplatin) to treat rectal cancer before routine surgery is performed to remove the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Rectal Cancer
Register for Updates
Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science
NCT00950118
Recruiting
The goal of this study is to identify genes that convey susceptibility to congenital diaphragmatic hernia in humans. The identification of such genes, and examination of their structure and function, will enable a delineation of molecular pathogenesis and, ultimately, prevention or treatment of congenital diaphragmatic hernia. There are many different possible modes of inheritance for congenital anomalies, including autosomal dominant, autosomal recessive, and multifactorial. Multi-factorial inh... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/30/2025
Locations: Washington University Medical Center/ St. Louis Children's Hospital, Saint Louis, Missouri
Conditions: Congenital Diaphragmatic Hernia
Register for Updates